MedTrace Logo

A Phase III Study of Re-Irradiation in Recurrent Glioblastoma

NCT01830101 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-03-16

No results posted yet for this study

Summary

The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiation.

Conditions

Interventions

DRUG

TMZ plus concurrent re-irradiation

DRUG

Temozolomide

low-dose temozolomide daily for one year

Sponsors & Collaborators

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Samir Patel, MD · Cross Cancer Institute

  • Gerald Lim, MD · Tom Baker Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-05-31
Completion
2017-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01830101 on ClinicalTrials.gov